Literature DB >> 26769884

Strategies for Primary Care Stakeholders to Improve Electronic Health Records (EHRs).

J Nwando Olayiwola1, Ashley Rubin2, Theo Slomoff2, Tem Woldeyesus2, Rachel Willard-Grace2.   

Abstract

The use of electronic health records (EHRs) and the vendors that develop them have increased exponentially in recent years. While there continues to emerge literature on the challenges EHRs have created related to primary care provider satisfaction and workflow, there is sparse literature on the perspective of the EHR vendors themselves. We examined the role of EHR vendors in optimizing primary care practice through a qualitative study of vendor leadership and developers representing 8 companies. We found that EHR vendors apply a range of strategies to elicit feedback from their clinical users and to engage selected users in their development and design process, but priorities are heavily influenced by the macroenvironment and government regulations. To improve the "marriage" between primary care and the EHR vendor community, we propose 6 strategies that may be most impactful for primary care stakeholders seeking to influence EHR development processes. © Copyright 2016 by the American Board of Family Medicine.

Keywords:  Delivery of Health Care; Electronic Health Records; Information Systems; Primary Health Care; Qualitative Research

Mesh:

Year:  2016        PMID: 26769884     DOI: 10.3122/jabfm.2016.01.150212

Source DB:  PubMed          Journal:  J Am Board Fam Med        ISSN: 1557-2625            Impact factor:   2.657


  2 in total

1.  Medical Scribes: Salvation for Primary Care or Workaround for Poor EMR Usability?

Authors:  Gordon D Schiff; Laura Zucker
Journal:  J Gen Intern Med       Date:  2016-09       Impact factor: 5.128

2.  Improved recording of work relatedness during patient consultations in occupational primary health care: a cluster randomized controlled trial using routine data.

Authors:  Salla Atkins; Tiia Reho; Nina Talola; Markku Sumanen; Mervi Viljamaa; Jukka Uitti
Journal:  Trials       Date:  2020-03-12       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.